Doximity, Inc. (DOCS) – What Are Brokerages Thinking About This Stock?

Doximity, Inc. (NYSE:DOCS) has been assigned an average recommendation of “Hold” from the twenty-five analysts that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $30.73.

A number of brokerages recently weighed in on DOCS. Canaccord Genuity Group set a $36.00 price target on shares of Doximity in a report on Friday, August 7th. Stifel Nicolaus set a $27.00 price objective on Doximity in a report on Tuesday, September 8th. Wells Fargo & Company lowered Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 price objective on the stock. in a research report on Monday, August 10th. Weiss Ratings upgraded Doximity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, October 6th. Finally, Truist Financial lifted their target price on Doximity from $19.00 to $24.00 and gave the company a “hold” rating in a research note on Thursday, August 13th.

Doximity Stock Down 3.9%

Doximity stock opened at $33.32 on Friday. The stock has a 50-day simple moving average of $28.95 and a 200 day simple moving average of $25.55. Doximity has a 12-month low of $17.15 and a 12-month high of $64.55. The stock has a market capitalization of $5.94 billion, a price-to-earnings ratio of 39.20, a P/E/G ratio of 27.12 and a beta of 1.29.

Doximity (NYSE:DOCS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.13. The business had revenue of $156.62 million for the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the company earned $0.36 EPS. As a group, sell-side analysts anticipate that Doximity will post 0.74 EPS for the current year.

Doximity News Summary

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Fiscal Q2 revenue was $174.5 million, ahead of the $170.8 million FactSet estimate, while EPS of $0.36 topped Zacks’ $0.34 consensus. Doximity also forecast Q3 revenue of $195–$196 million and FY2027 revenue of $678–$683 million, both above analyst expectations. Fiscal 2027 second-quarter results
• Positive Sentiment: Management cited record engagement, a 51% adjusted EBITDA margin, and adoption of its AI suite by more than 190 health systems. The company is expanding its offering with UpToDate and DoseCheck. Company results and management commentary
• Neutral Sentiment: Despite the earnings beat, EPS was down from $0.45 a year earlier. A report noted that DOCS stock fell after the sales beat, suggesting the positive results and guidance did not fully satisfy investors’ expectations. Doximity sales beat estimates but stock drops
• Negative Sentiment: Multiple law firms highlighted a pending securities class action and a November 16 lead-plaintiff deadline. The lawsuit alleges Doximity misrepresented the Newsfeed product’s contribution to revenue growth and its competitive position; these claims have not been established in court. The litigation adds uncertainty. Securities class action notice

Insider Activity

In related news, Director Kira Wampler sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $32.89, for a total value of $65,780.00. Following the transaction, the director owned 27,923 shares in the company, valued at $918,387.47. This trade represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,613 shares of the company’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total transaction of $80,166.84. Following the transaction, the chief accounting officer owned 101,432 shares in the company, valued at approximately $3,111,933.76. The trade was a 2.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 13,750 shares of company stock valued at $386,310 over the last 90 days. 31.80% of the stock is owned by company insiders.

Institutional Trading of Doximity

A number of institutional investors have recently bought and sold shares of DOCS. Jefferies Financial Group Inc. lifted its stake in shares of Doximity by 526.3% in the 3rd quarter. Jefferies Financial Group Inc. now owns 179,400 shares of the company’s stock valued at $5,084,000 after purchasing an additional 150,755 shares during the period. Riverbridge Partners LLC grew its stake in shares of Doximity by 7.9% during the third quarter. Riverbridge Partners LLC now owns 303,539 shares of the company’s stock worth $8,602,000 after purchasing an additional 22,320 shares during the period. Lido Advisors LLC acquired a new stake in shares of Doximity during the third quarter worth $281,000. M&G PLC grew its stake in shares of Doximity by 96.4% during the third quarter. M&G PLC now owns 577,196 shares of the company’s stock worth $16,161,000 after purchasing an additional 283,296 shares during the period. Finally, Fulcrum Asset Management LLP increased its holdings in Doximity by 17,401.8% in the third quarter. Fulcrum Asset Management LLP now owns 66,857 shares of the company’s stock valued at $1,773,000 after purchasing an additional 66,475 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.

The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.

Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.